UK Biotechs Maintain Fundraising During Pandemic
Sector's First NASDAQ IPO Of 2020 Expected Soon
Buoyed by belief in its strengths, the UK biotech sector has defied the pandemic over the last three months – but smaller firms are still strapped for cash.
You may also be interested in...
The UK major is getting access to Silence's small interfering RNA (siRNA) platform while the London-based biotech is getting further validation of its technology and a considerable pile of cash.
A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.
The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth